Related Experiment Video

Updated: May 13, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular

Qian Zhou1, Chi Hang Wong, Cecilia Pik Yuk Lau

  • 1Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong ; Cancer Drug Testing Unit, State Key Laboratory of Oncology in South China, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.

International Journal of Hepatology
|March 20, 2013
PubMed

Insights

Combining everolimus (mTOR inhibitor) and patupilone (microtubule agent) shows potent antitumor activity against hepatocellular carcinoma (HCC). This dual-targeting strategy enhances growth inhibition and apoptosis, offering a promising therapeutic approach for HCC.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Hepatocellular carcinoma (HCC) presents challenges in treatment, with mammalian target of rapamycin (mTOR) and microtubules as potential therapeutic targets.
  • Activation of the PI3K/Akt/mTOR pathway is linked to resistance against microtubule-targeting agents.

Purpose of the Study:

  • To evaluate the combined antitumor activity of an mTOR inhibitor (everolimus) and a novel microtubule-stabilizing agent (patupilone) in hepatocellular carcinoma models.
  • To investigate the synergistic effects and underlying mechanisms of this cotargeting strategy.

Main Methods:

  • In vitro studies assessed the effects of everolimus and patupilone, individually and in combination, on HCC cell growth.
  • In vivo studies utilized Hep3B xenografts to evaluate the antitumor efficacy of the combination therapy.
  • Mechanistic studies examined apoptosis induction and antiangiogenic activity.

Main Results:

  • Both everolimus and patupilone demonstrated dose-dependent suppression of HCC cell growth individually.
  • The combination of everolimus and patupilone resulted in enhanced growth inhibition (60-87%) in vitro.
  • In vivo, the combination therapy showed significantly greater antitumor activity than single agents, accompanied by increased apoptosis and antiangiogenic effects.

Conclusions:

  • The cotargeting of mTOR with everolimus and microtubules with patupilone exhibits potent antitumor activity in HCC models.
  • This combination strategy represents a promising therapeutic approach for hepatocellular carcinoma, warranting further clinical investigation.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...